Following a market correction, ATMPs are entering a more selective phase where scientific promise must be matched by clear execution. This session will examine what differentiates companies that get funded, scaled, and ultimately acquired. The discussion will focus on investor selection criteria at seed and Series A, including data thresholds, platform differentiation, and capital efficiency. It will also address the role of delivery and manufacturing in enabling—or limiting—scalability. From a pharma perspective, the panel will highlight what drives partnering and acquisition decisions, and why many ATMP companies fail to reach that stage. Bringing together investors, founders, pharma, and manufacturing experts, the session will provide a practical framework to assess ATMP opportunities in today’s environment.
- Regulatoria: AEMPS o alguna empresa experta en el tema (ej.: Asphalion o Clarek + Modet). TBC
- Legislación: un perfil que conozca la legislación y marco europeo (aquí sugeriríamos alguien de Vinces) TBC
5. Legislative perspective: VINCES???
